Dual Antiplatelet Therapy in Acute Branch Atheromatous Disease ( BAD )‐Related Stroke: A Multicenter Propensity‐Matched Cohort Analysis
Duale Plättchenhemmung bei akutem BAD-assoziiertem Schlaganfall: multizentrische, propensity-gematchte Kohortenanalyse
CNS Neuroscience & Therapeutics · 2026-07 · 32 (7)
DOI: 10.1002/cns.71005 ↗Auf einen Blick
Bei BAD-assoziiertem akutem Schlaganfall war DAPT numerisch häufiger mit einem exzellenten Outcome verbunden als SAPT, statistisch aber nicht überlegen. Ein erhöhtes Blutungsrisiko wurde nicht beobachtet.
Fragestellung
Vergleich von DAPT und SAPT bei Patient:innen mit BAD-assoziiertem Schlaganfall hinsichtlich klinischer Outcomes und Sicherheit.
Methode
Multizentrische prospektive Kohortenanalyse aus der BAD-Studie; Propensity-Score-Matching zum Ausgleich der Ausgangsmerkmale.
Ergebnisse
449 Patient:innen. Nach Matching 112 in der SAPT- und 171 in der DAPT-Gruppe. Exzellentes Outcome: 69,6 % vs. 79,5 %; OR 0,590 (95 %-KI 0,341–1,022; p = 0,059). Keine signifikanten Unterschiede in anderen Wirksamkeitsendpunkten; keine erhöhte Blutungsrate unter DAPT.
Schlussfolgerung der Autor:innen
Bei akutem BAD-assoziiertem Schlaganfall war DAPT sicher, aber einem SAPT für ein exzellentes funktionelles Outcome statistisch nicht überlegen; ein möglicher Nutzen sollte weiter untersucht werden.
Kernaussagen
- Exzellentes Outcome: 69,6 % mit SAPT vs. 79,5 % mit DAPT
- OR 0,590 (95 %-KI 0,341–1,022; p = 0,059)
- Unter DAPT kein erhöhtes Blutungsrisiko beobachtet
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 30.06.2026. Verfasst von Haizhou Hu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical …. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Stroke, Dual Anti-Platelet Therapy, Plaque, Atherosclerotic. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, Noncommunicable Chronic Diseases-National Science and Technology Major Project, Special Project on Clinical Scientific Research of the Medical and Health Technology Development and Research Center, National Health Commission.
Themen: Schlaganfall
Abstract (Originalsprache)
Aims
The optimal antiplatelet regimen for branch atheromatous disease (BAD)‐related stroke remains uncertain. This study aimed to compare the clinical outcomes of dual antiplatelet therapy (DAPT) vs. single antiplatelet therapy (SAPT) in these patients.
Methods
From the multicenter prospective BAD‐study, we collected consecutive patients with BAD who received DAPT and SAPT. Propensity score matching (PSM) was used to balance baseline characteristics. The primary efficacy endpoint was an excellent outcome, defined as a modified Rankin Scale score of 0 to 1 at 90 days. The safety endpoint was bleeding events within 7 or 90 days.
Results
A total of 449 patients were enrolled in the analysis, with a median age of 60 years and a median National Institutes of Health Stroke Scale score of 3 at admission. After PSM, there were 112 patients in the SAPT group and 171 patients in the DAPT group, with well‐balanced baseline characteristics. Excellent outcome occurred in 69.6% of the SAPT group and 79.5% of the DAPT group (odds ratio, 0.590; 95% confidence interval, 0.341 to 1.022; p = 0.059). No significant differences were observed in other efficacy outcomes between the two groups. In exploratory subgroup analysis, no significant treatment‐by‐subgroup interactions were observed, and after correction for multiple comparisons, no within‐subgroup differences remained statistically significant. No increased bleeding risk was observed in DAPT.
Conclusion
In acute BAD‐related stroke, DAPT was safe but not statistically superior to SAPT for excellent functional outcome; however, its numerical trend toward benefit warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, China.
- Department of Neurology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Department of Neurology, Xuanwu Jinan Hospital, Jinan, China.
- Department of Radiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
ORCID-Profile: Haizhou Hu, Jun Ni
Förderung
- National High Level Hospital Clinical Research Funding
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Special Project on Clinical Scientific Research of the Medical and Health Technology Development and Research Center, National Health Commission
Zitieren
APA
Hu, H., Li, S., Zhang, Y., Sha, Y., Zhou, Y., Feng, F., Zhu, Y., Zhou, L., Peng, B., Ni, J., & BAD‐study investigators (2026). Dual Antiplatelet Therapy in Acute Branch Atheromatous Disease ( BAD )‐Related Stroke: A Multicenter Propensity‐Matched Cohort Analysis. CNS Neuroscience & Therapeutics, 32(7). https://doi.org/10.1002/cns.71005
Vancouver
Hu H, Li S, Zhang Y, Sha Y, Zhou Y, Feng F, et al. Dual Antiplatelet Therapy in Acute Branch Atheromatous Disease ( BAD )‐Related Stroke: A Multicenter Propensity‐Matched Cohort Analysis. CNS Neuroscience & Therapeutics. 2026;32(7). doi:10.1002/cns.71005
BibTeX
@article{Hu2026,
author = {Hu, Haizhou and Li, Shengde and Zhang, Yu and Sha, Yuhui and Zhou, Yaping and Feng, Feng and Zhu, Yicheng and Zhou, Lixin and Peng, Bin and Ni, Jun and BAD‐study investigators, BAD‐study investigators},
title = {Dual Antiplatelet Therapy in Acute Branch Atheromatous Disease ( BAD )‐Related Stroke: A Multicenter Propensity‐Matched Cohort Analysis},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {7},
doi = {10.1002/cns.71005}
}
EUVIMED